Лозап АМ

Quick links

Choose a section

Quick links to important sections

Advertisements

Лозап АМ

Selected form

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Лозап АМ

What is Лозап АМ? Definition and Fixed-Dose Classification

Property Description
Active Ingredients Amlodipine, Losartan
Form Tablet (Fixed-Dose Combination)
Pharmacological Class Calcium Channel Blocker (CCB) and Angiotensin II Receptor Blocker (ARB)
Common Use Antihypertensive action
Origin Synthetic Compound

Лозап АМ is a Fixed-Dose Combination (FDC) Antihypertensive Agent provided as a single tablet intended for oral administration. This product is a prescription-only medication classified as a synthetic compound designed for blood pressure management. The inclusion of dual-therapy agents in established lists of essential medicines underscores the accepted strategy of combining pharmacological mechanisms for comprehensive control.

This FDC structure ensures the patient receives two different, complementary types of blood pressure medication in one preparation. As an FDC, Лозап АМ streamlines the therapeutic approach, which is clinically recognized for often leading to improved patient adherence compared to managing multiple separate pills.


Composition: Amlodipine and Losartan Dual Therapy

The medication is composed of two primary active ingredients, Amlodipine and Losartan, typically formulated as the salts Amlodipine besylate and Losartan potassium, respectively. This combination is specifically known for pairing a Dihydropyridine Calcium Channel Blocker (Amlodipine) with an Angiotensin II Receptor Blocker (Losartan), two distinct pharmacological classes frequently used together.

The efficacy of combining an ARB and a CCB is recognized through clinical evaluation. This pairing offers significant benefits in achieving and maintaining target blood pressure goals. This supports the principle that combining these two distinct classes is a widely accepted strategy. The synthetic origin of the active ingredients facilitates precise, standardized dosing in the solid tablet form.


General Purpose of This Combination Antihypertensive Agent

The general purpose of Лозап АМ is to deliver a robust and comprehensive antihypertensive action, effectively reducing and controlling elevated blood pressure, which is a typical requirement for adults experiencing chronic hypertension. This goal is achieved because the medication employs a dual strategy: Amlodipine promotes peripheral arterial vasodilation to directly relax and widen the vessels, while Losartan blocks the body's natural signals that cause the vessels to tighten by inhibiting Angiotensin II. The combination of these two complementary mechanism principles provides a sustained reduction in the resistance against which the heart pumps, thereby lessening cardiovascular strain.

Regulatory References

  1. WHO Essential Medicines Lists
Advertisements

What side effects are possible with Лозап АМ?

Possible Side Effects and Safety Information

The safety profile of Losap AM (Losartan/Amlodipine) is based on adverse reactions reported for its active components. Reactions are generally classified by frequency, with some requiring immediate medical attention.


Key Adverse Reactions and Frequency

Adverse reactions are classified according to frequency observed in clinical data:

  • Very Common (≥10%): Fatigue, weakness, diarrhea, cough, upper respiratory tract infection, anemia, and hypoglycemia.
  • Common (1% to <10%): Dizziness, headache, nausea, abdominal pain, hypotension, and peripheral edema (swelling of hands/feet).
  • Uncommon/Rare: Palpitations, skin rash, pruritus (itching), muscle cramps, and tinnitus.

Serious and Clinically Significant Risks

Angioedema (swelling of the face, lips, tongue, or throat, potentially causing difficulty breathing) is a serious, though rare, reaction requiring emergency medical care. Severe hypotension (significant drop in blood pressure, potentially leading to fainting) is also a risk, especially at the start of therapy or in volume-depleted patients. Losartan may cause hyperkalemia (elevated potassium levels) and worsening renal function in susceptible individuals, necessitating laboratory monitoring.


Population-Specific Safety Considerations

Pregnancy: This medication is strictly contraindicated during the second and third trimesters of pregnancy due to the risk of injury and death to the developing fetus. Female patients must be monitored for pregnancy and advised on the risks. Patients with Liver Impairment: Lower initial doses may be recommended due to reduced clearance. Volume-Depleted Patients: A lower starting dose is necessary to minimize the risk of symptomatic hypotension.

Advertisements

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — official regulatory information for Лозап АМ

Feature Official Regulatory Statement
Documented overdose presentations: Marked and prolonged systemic hypotension, excessive peripheral vasodilatation, and either tachycardia (reflex) or bradycardia (due to vagal stimulation).
Physiological systems affected (as stated in label): Primarily the Cardiovascular system (hypotension, shock, heart rate changes).
Dose-related or exposure-related factors (if applicable): Regulatory data on overdosage is based on the individual components; information refers to the risks of gross overdosage of Amlodipine.
Population-specific overdose notes (if applicable): Neither Losartan nor its active metabolite can be removed by hemodialysis due to high protein binding.
Emergency-response statements (as written in official documents): Seek medical attention immediately at the first sign of any adverse drug reaction.
When immediate medical help is required (label-derived phrasing only): When symptoms suggest clinically significant hypotension, or if the overdose results in potential for shock with fatal outcome.

Overdose classifications (high-level)

Classification Official Regulatory Statement
Severity classification (as defined in official documents): May result in shock with fatal outcome (Amlodipine component).
Regulatory basis (EMA / FDA / etc.): Information is derived from the official prescribing information for the individual active ingredients.
Overdose-context constraints (as defined in official documents): If symptomatic hypotension occurs, immediate supportive treatment must be instituted.

Resulting overdose structure

Official overdose statements:

  • The most likely signs of Losartan overdosage are hypotension and tachycardia; however, bradycardia could occur from vagal stimulation.
  • Amlodipine overdosage may result in excessive peripheral vasodilatation and prolonged systemic hypotension that can progress to shock.
  • Clinically significant hypotension calls for active cardiovascular support, including frequent monitoring of cardiac and respiratory function, elevation of extremities, and attention to fluid volume.
  • If hypotension remains unresponsive to conservative measures, vasopressors should be considered; activated charcoal is indicated after oral intake.

Connection to the overall overdose profile:

Regulatory documents define the overdose profile by the severe hypotensive effects arising from the combined action of Losartan and Amlodipine. The official guidance emphasizes that stabilization of the cardiovascular system must be the priority, requiring the initiation of active monitoring and immediate supportive treatment if symptomatic hypotension occurs.

Advertisements

Therapeutic Uses of Лозап АМ

What Лозап АМ Treats: Main Uses and Benefits

Лозап АМ is a dual-therapy medication that generally supports the management of chronic cardiovascular conditions, focusing on effective blood pressure control and long-term protection against complications. This combination is typically utilized in clinical settings where single-agent therapy has been deemed inadequate.

The medication is commonly used to help with effective blood pressure control in adults with chronic essential hypertension where the condition is considered relevant when symptomatic manifestations are inadequately controlled using either Amlodipine or Losartan as a single agent. It is relevant for managing conditions that present with systemic or localized discomfort related to high blood pressure, and is also relevant for individuals managing recurrent chest discomfort, such as chronic stable angina or vasospastic angina.

The therapy is relevant for supporting cardiovascular and organ protection in these conditions. It is relevant for easing the symptoms related to chronic hypertension, and may assist with managing the long-term cardiovascular burden.


Quick Fact: Therapeutic Focus

This combination is generally applied in settings where symptoms are related to heightened physiological activity and symptoms that interfere with daily functioning. It assists with maintaining functional stability and supports general well-being during symptomatic phases.

Advertisements

Eligibility and Restrictions for Use

Eligibility Map: Who Can and Cannot Use Лозап АМ — Official Regulatory Information

Category Official Regulatory Statement
Populations for whom use is allowed Adults (18 years and older) with hypertension are the eligible population.
Populations for whom use is not recommended Patients in the first trimester of pregnancy and nursing mothers (breastfeeding).
Populations for whom use is contraindicated Patients with known hypersensitivity to Losartan, Amlodipine, or other dihydropyridines. Women in the second and third trimesters of pregnancy. Patients with severe hepatic impairment. Those with severe hypotension, shock, or obstruction of the left ventricular outflow tract (e.g., severe aortic stenosis). Concomitant use with aliskiren is contraindicated in patients with diabetes or renal impairment.
Age-related eligibility rules Children and Adolescents (Under 18 years) are not recommended or contraindicated as safety and efficacy have not been established for the fixed-dose combination.
Condition-specific eligibility rules Severe Hepatic Impairment is an absolute contraindication. Use requires caution in patients with severe renal impairment or a history of angioedema related to prior ARB/ACE-inhibitor therapy.

Eligibility Classifications (High-Level)

Official eligibility statements are structured into Contraindicated (highest non-eligibility severity), Not Recommended (conditional restriction, e.g., pediatric/pregnancy), and Use with Caution (conditional use, e.g., organ impairment). These classifications define regulatory boundaries based on Hypersensitivity, Reproductive Status, Cardiovascular Instability, and Critical Organ-Function Status to determine who is officially permitted to use the medicine.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

This medication contains Losartan (an Angiotensin II Receptor Blocker) and Amlodipine (a Calcium Channel Blocker), and its interaction profile combines the risks associated with both active components.

Interactions Primarily Affecting Losartan (Risk of Hyperkalemia and Renal Issues):

Interacting Product Category Clinical Significance and Constraint
Potassium-sparing Diuretics (e.g., Spironolactone), Potassium Supplements, or Salt Substitutes Concomitant use increases the risk of hyperkalemia (high potassium levels). Close monitoring of serum potassium is necessary.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including COX-2 inhibitors May lead to a reduced blood pressure-lowering effect and increase the risk of renal function deterioration, especially in patients with pre-existing impaired kidney function.
Dual Renin-Angiotensin System Blockade (e.g., with Aliskiren in diabetic patients or ACE Inhibitors) This combination is generally contraindicated (Aliskiren in diabetics) or strongly discouraged due to increased risk of severe hypotension, hyperkalemia, and renal impairment.
Lithium Losartan can reduce the elimination of lithium, potentially leading to lithium toxicity; serum lithium levels must be closely monitored.

Interactions Primarily Affecting Amlodipine (Risk of Increased Exposure):

Interacting Product Category Clinical Significance and Constraint
Simvastatin (a cholesterol-lowering medication) Amlodipine increases the systemic exposure of Simvastatin. To reduce the risk of muscle toxicity (myopathy/rhabdomyolysis), the Simvastatin dose must not exceed 20 mg daily when co-administered.
Strong/Moderate CYP3A4 Inhibitors (e.g., Ketoconazole, Diltiazem) These agents can significantly increase the plasma concentration of Amlodipine, leading to a higher risk of hypotension. Monitoring is required.
Grapefruit/Grapefruit Juice Consumption should generally be avoided as it can increase the systemic exposure of Amlodipine, potentially leading to enhanced effects or severe hypotension.
Advertisements

Mechanism of Action

Selective Blockade of Angiotensin II Receptors

This domain covers the action of Losartan, which selectively targets and blocks the Angiotensin II type 1 (AT1) receptors in vascular smooth muscle and other tissues. This mechanism suppresses the vasoconstrictor and aldosterone-secreting effects of the natural hormone Angiotensin II, resulting in the inhibition of Angiotensin II-mediated signaling within the vascular system.


Modulation of Vascular Calcium Channel Activity

This mechanistic domain describes the action of Amlodipine, which selectively engages L-type voltage-dependent calcium channels in the cell membranes of vascular smooth muscle. This modification of ion influx inhibits the key process of excitation-contraction coupling in the arterial wall, resulting in the reduction of vascular smooth muscle contraction and consequential vasodilation.


Systemic Hemodynamic Pathway Adjustment

The dual mechanistic influences result in composite effects on systemic vascular dynamics. This complementary mechanism reduces overall total peripheral resistance and limits the impact of excessive constrictive mediator activity, affecting systemic hemodynamics through the modification of total peripheral resistance.

Advertisements

Dosage and Administration Information

Official Administration Guidelines for Лозап АМ

The administration of Лозап АМ, a fixed-dose combination of Amlodipine and Losartan, is structured around standardized clinical parameters to ensure consistent use. The medication is delivered via the oral route, utilizing a film-coated tablet that must be swallowed whole. This method ensures the simultaneous delivery of both active components, regardless of whether the patient takes the dose with or without food.

Dosing Schedule and Regimen

The standard protocol mandates a Once Daily (q.d.) dosing frequency for the long-term management of chronic conditions. Treatment typically initiates with one tablet of a lower strength, such as 5 mg Amlodipine / 50 mg Losartan Potassium. If adequate control is not achieved, dosage titration is performed after a minimum interval of one to two weeks, guided by the patient's response, up to the maximum established daily strength of 10 mg Amlodipine / 100 mg Losartan Potassium.

Procedural Constraints and Special Populations

If a dose is missed, it should be taken immediately unless it is nearly time for the next scheduled dose, in which case the missed dose is skipped. The doubling of doses is strictly prohibited. Furthermore, official guidelines advise specific caution and potential starting dose adjustments for certain populations. This includes initiating therapy with a lower dose for older adults and individuals with documented hepatic impairment, due to altered drug clearance. These instructions collectively establish the general framework for the medication's administration.

Advertisements

Recent Clinical Evidence

The research on Лозап АМ (Losartan/Amlodipine Fixed-Dose Combination or FDC) primarily focuses on assessing its structure in a controlled research setting. The evidence is derived from formal clinical trials and systematic studies designed to explore how outcomes changed in observed populations.


Evidence for use in Chronic Essential Hypertension

The core evidence for this fixed-dose combination stems from short-term, randomized controlled trials (RCTs). Researchers examined the FDC against Losartan or Amlodipine monotherapy in adults whose chronic high blood pressure was considered inadequately controlled by a single agent. The primary outcomes measured were the change in average systolic and diastolic blood pressure in the study groups and the proportion of patients who reached a standardized target BP goal. Clinical research documented a pattern where the combination was associated with different measured blood pressure changes compared to monotherapy. This research observed a difference in the proportion of patients reaching predefined target levels.


Regulatory Equivalence and Research Limitations

Dedicated regulatory research, known as bioequivalence studies, was conducted on healthy volunteers to confirm that the FDC tablet is pharmacokinetically comparable to taking the two components as separate pills, fulfilling a key regulatory requirement. This type of research, however, provides no data on clinical efficacy.

The primary evidence base focused on blood pressure changes over short intervals (typically 8 to 12 weeks). Long-term effects are not fully established by the primary clinical trials, and evidence regarding long-term outcomes, such as changes in cardiovascular status or stroke occurrence, often relies on data from observational settings. While studies included older adults, data for certain specific groups, such as pregnant women or those with severe comorbidities, remain insufficient.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Лозап АМ (FAQ)

Q: How does Losap AM differ from regular Losap or Amlodipine?

Official product information states that Losap AM is a Fixed-Dose Combination (FDC). This means it is a single tablet that contains two active components: Losartan and Amlodipine. Losap (monotherapy) contains only Losartan, and Amlodipine (monotherapy) contains only Amlodipine.

Q: What side effects of Losap AM occur most often?

According to clinical data, the very common side effects are those that occur in 10% or more of patients. These most frequently reported reactions include fatigue, weakness, diarrhea, cough, upper respiratory tract infection, anemia, and hypoglycemia.

Q: Is there scientific data on the effect of Losap AM on reducing the risk of heart attack or stroke?

Clinical studies focusing specifically on the fixed combination primarily assessed changes in blood pressure over the short term. Evidence regarding long-term outcomes, such as a reduction in the risk of stroke or heart attack, often relies on data from studies conducted with the individual components or from observational settings.

Q: How long does the effect of Losap AM last after taking it?

Losap AM is designed for once-daily dosing. The antihypertensive effect of Amlodipine, one of the components, is known to be sustained for at least 24 hours following a single daily dose, which supports the prescribed dosing schedule.

Q: Can I take Losap AM only in the morning, or do I need to divide the dose?

Official dosing guidelines state that the medicine is intended for use once a day. The official regimen does not permit dividing the tablet or taking the dose twice daily. The specific time of day (morning or evening) should be determined in consultation with a healthcare provider.

Q: How long does it take to see the effect of Losap AM?

Stable concentrations of Amlodipine (one of the components) in the body, which lead to its full therapeutic action, are typically achieved after 7 to 10 days of consistent daily intake.

Q: Is this medicine considered a 'blocker' or a 'sartan'?

Regulatory labels classify this medicine as belonging to two pharmacological classes. Amlodipine is a Calcium Channel Blocker (often informally referred to as a blocker), and Losartan is an Angiotensin II Receptor Blocker (often informally referred to as a sartan).

Q: Is it true that Losap AM must be taken for life?

Official patient information emphasizes the importance of continuing to take the medicine as prescribed by a healthcare provider. This continuity is generally necessary for the ongoing management of chronic high blood pressure, according to official information.

Q: Is it safe to take Losap AM if I have diabetes?

Official documents state that the use of this fixed combination with the medicine Aliskiren is strictly contraindicated (not allowed) in patients with diabetes. In all other scenarios, determining eligibility requires careful evaluation by a healthcare provider.

Q: If blood pressure has normalized, should I continue taking Losap AM?

The official patient information emphasizes the need to continue taking the medication to ensure the smooth and long-term control of blood pressure, even after it has normalized. Decisions regarding treatment duration are based on medical evaluation.

Q: Can Losap AM cause a dry cough, like other blood pressure medications?

A general cough is listed as a potential side effect in the official prescribing information. However, Losartan, being an Angiotensin II Receptor Blocker, is typically associated with a lower risk of the specific dry, persistent cough commonly linked to the ACE inhibitor class of medicines.

Q: Is Losap AM suitable for treating hypertension in young people?

The medication is officially authorized for use in adults (age 18 and older). Official documents do not specify differences in effectiveness or safety across various adult age groups.

Q: Can Losap AM cause dizziness or weakness?

Yes, both dizziness and weakness (or fatigue) are explicitly listed in the official documentation among the frequently reported adverse reactions observed in clinical data.

Q: Is it true that Losap AM can affect potency in men?

Erectile dysfunction (impotence) is listed as a rare side effect in the official documentation for Losartan, one of the active ingredients.

Q: Do I need to follow a special diet when taking Losap AM?

Official regulatory warnings state that the consumption of grapefruit juice should be avoided. Additionally, patients should use caution with products containing high levels of potassium (such as potassium-containing salt substitutes) due to the Losartan component.

Q: Can Losap AM cause an allergic reaction?

Yes, allergic reactions, including rash, itching, and angioedema (swelling), are listed as potential side effects in the documentation. Known hypersensitivity (allergy) to either of the components is listed as a contraindication for taking the medicine.

Q: What are the signs of an overdose of Losap AM?

Official product documentation states that an overdose may cause a marked and severe drop in blood pressure (hypotension) and changes in heart rhythm, such as either a rapid heart rate (tachycardia) or a slow heart rate (bradycardia).

Q: What organs, besides the heart and blood vessels, does Losap AM protect?

Losartan, one of the components, has official indications related to the protection of the kidneys in specific populations, in addition to its primary action on the vascular system.

Q: Why do doctors often prescribe combination drugs like Losap AM?

Fixed combination medicines like Losap AM are recognized for their ability to provide more effective blood pressure control through the use of two complementary mechanisms of action. The structure is recognized for potentially supporting patient adherence to the treatment regimen compared to taking two separate pills.

Q: Are there restrictions on driving a car when taking Losap AM?

Official safety information indicates that the ability to drive or operate machinery may be impaired if the patient experiences side effects such as dizziness, headache, fatigue, or nausea. Caution is needed if these effects occur.

Q: Is special monitoring required when switching from another drug to Losap AM?

Regulatory documentation requires specific caution and potential dose adjustment when starting therapy in patients with pre-existing conditions like liver impairment or fluid volume depletion. Decisions regarding transitioning from other medications are based on individual medical evaluation and dose adjustments performed by a healthcare provider.

Q: Can Losap AM cause insomnia?

Yes, insomnia (difficulty sleeping) is listed in the official documentation as an uncommon adverse reaction associated with the use of the medicine.

Q: Do I need to take Losap AM at the same time every day?

Official guidelines state that it may be easier for patients to take the medication at the same time every day to help prevent missed doses and ensure treatment consistency.

Advertisements

How should Лозап АМ be stored and disposed of?

How to Store and Dispose of Лозап АМ?

The official storage conditions for Лозап АМ tablets are designed to maintain the product's quality and stability, as defined by regulatory authorities.

Storage Requirements

This medicine must be stored at a temperature not exceeding 25 C (77 F). Storage environments that are either refrigerated or frozen are prohibited, as are temperatures above the specified limit.

The tablets should be kept in their original container or outer carton to ensure protection from both light and moisture. As a mandatory safety measure for all prescription medicines, Лозап АМ must be kept out of the sight and reach of children.

Disposal Instructions

Any unused or expired Лозап АМ must be disposed of according to local requirements for pharmaceutical waste, as instructed in the product labeling. The medication must not be discarded into household waste or flushed down the toilet, to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Лозап АМ found in:

A-Z Index: